2cureX AB (publ) (2CUREX.ST)
SEK 0.35
(4.19%)
SEK 0.35
(4.19%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 36.51 Million SEK | 13.33% |
| 2022 | 32.22 Million SEK | 41.32% |
| 2021 | 22.8 Million SEK | 207.37% |
| 2020 | 7.41 Million SEK | -15.21% |
| 2019 | 8.74 Million SEK | 3.71% |
| 2018 | 8.43 Million SEK | 109.85% |
| 2017 | 4.02 Million SEK | 38.48% |
| 2016 | 2.9 Million SEK | -7.84% |
| 2015 | 3.14 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.6 Million SEK | -59.33% |
| 2024 Q2 | 3.6 Million SEK | 0.0% |
| 2023 Q2 | 8.74 Million SEK | 3.39% |
| 2023 FY | 36.51 Million SEK | 13.33% |
| 2023 Q4 | 8.85 Million SEK | -5.17% |
| 2023 Q3 | 9.33 Million SEK | 6.72% |
| 2023 Q1 | 8.46 Million SEK | 17.89% |
| 2022 Q2 | 7.55 Million SEK | -6.59% |
| 2022 FY | 32.22 Million SEK | 41.32% |
| 2022 Q4 | 7.17 Million SEK | -23.71% |
| 2022 Q3 | 9.4 Million SEK | 24.52% |
| 2022 Q1 | 8.08 Million SEK | 10.51% |
| 2021 Q3 | 6.55 Million SEK | 3.88% |
| 2021 Q2 | 6.31 Million SEK | 141.02% |
| 2021 Q1 | 2.61 Million SEK | 79.07% |
| 2021 FY | 22.8 Million SEK | 207.37% |
| 2021 Q4 | 7.31 Million SEK | 11.64% |
| 2020 Q3 | 1.1 Million SEK | -51.58% |
| 2020 Q2 | 2.28 Million SEK | -11.35% |
| 2020 FY | 7.41 Million SEK | -15.21% |
| 2020 Q4 | 1.46 Million SEK | 32.43% |
| 2020 Q1 | 2.57 Million SEK | 29.77% |
| 2019 FY | 8.74 Million SEK | 3.71% |
| 2019 Q1 | 1.76 Million SEK | 4.89% |
| 2019 Q3 | 2.02 Million SEK | -32.04% |
| 2019 Q4 | 1.98 Million SEK | -2.17% |
| 2019 Q2 | 2.98 Million SEK | 69.38% |
| 2018 Q1 | 2.94 Million SEK | 57.07% |
| 2018 FY | 8.43 Million SEK | 109.85% |
| 2018 Q3 | 715 Thousand SEK | -76.91% |
| 2018 Q2 | 3.09 Million SEK | 5.02% |
| 2018 Q4 | 1.67 Million SEK | 134.69% |
| 2017 Q4 | 1.87 Million SEK | 525.63% |
| 2017 FY | 4.02 Million SEK | 38.48% |
| 2017 Q1 | 1.54 Million SEK | 80.9% |
| 2017 Q2 | 1.23 Million SEK | -20.54% |
| 2017 Q3 | 300 Thousand SEK | -75.61% |
| 2016 FY | 2.9 Million SEK | -7.84% |
| 2016 Q4 | 855.7 Thousand SEK | 0.0% |
| 2015 FY | 3.14 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.588% |
| AcouSort AB (publ) | 25.87 Million SEK | -41.127% |
| Active Biotech AB (publ) | 44.8 Million SEK | 18.503% |
| Alzinova AB (publ) | 36.39 Million SEK | -0.335% |
| Amniotics AB (publ) | 29.07 Million SEK | -25.612% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -149.219% |
| BioArctic AB (publ) | 89.62 Million SEK | 59.256% |
| Camurus AB (publ) | 1.05 Billion SEK | 96.554% |
| Cantargia AB (publ) | 290.01 Million SEK | 87.408% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -66.787% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -28.919% |
| Genovis AB (publ.) | 88.19 Million SEK | 58.595% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 68.265% |
| Mendus AB (publ) | 129.13 Million SEK | 71.722% |
| Kancera AB (publ) | 63.07 Million SEK | 42.106% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -561.678% |
| LIDDS AB (publ) | 27.75 Million SEK | -31.587% |
| Lipum AB (publ) | 37.3 Million SEK | 2.115% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -403.419% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 73.131% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -122.657% |
| NextCell Pharma AB | -576.01 Thousand SEK | 6439.721% |
| OncoZenge AB (publ) | 15.9 Million SEK | -129.601% |
| Saniona AB (publ) | 1.07 Million SEK | -3290.715% |
| Simris Alg AB (publ) | 38.64 Million SEK | 5.497% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 88.642% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 89.789% |
| Xintela AB (publ) | 57.31 Million SEK | 36.287% |
| Ziccum AB (publ) | 27.87 Million SEK | -30.992% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -402.449% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 79.906% |
| CombiGene AB (publ) | 44.14 Million SEK | 17.275% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 74.461% |
| Intervacc AB (publ) | 79.78 Million SEK | 54.229% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 88.108% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 14.341% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -106.515% |
| Corline Biomedical AB | 30.16 Million SEK | -21.049% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 37.072% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 56.092% |
| Aptahem AB (publ) | 10.01 Million SEK | -264.708% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 72.888% |
| Fluicell AB (publ) | 28.61 Million SEK | -27.609% |
| Biovica International AB (publ) | 133.72 Million SEK | 72.691% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -84.528% |
| Abliva AB (publ) | 27.86 Million SEK | -31.049% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 81.128% |
| I-Tech AB | 40.14 Million SEK | 9.042% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 95.751% |
| Cyxone AB (publ) | 28.21 Million SEK | -29.432% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 66.61% |
| Biosergen AB | 26.8 Million SEK | -36.215% |
| Nanologica AB (publ) | 69.88 Million SEK | 47.747% |
| SynAct Pharma AB | 224.49 Million SEK | 83.733% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 17.335% |
| BioInvent International AB (publ) | 441.4 Million SEK | 91.727% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -52.449% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 87.397% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -364.826% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 67.075% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -148.422% |